XOMA Corporation is a biopharmaceutical company incorporated in 1981. XOMA Corporation develops biopharmaceutical products to treat serious bacterial and fungal infections, infectious complications, and immune system diseases including organ transplant rejection. The company's core technology is in the development and manufacturing of recombinant proteins and peptides, primarily those derived from the host-defense protein BPI (bactericidal/permeability-increasing protein). XOMA's technologies also include monoclonal antibodies, immunofusion molecules, and mammalian and bacterial cell expression systems. Through a collaborative agreement with Genentech, XOMA is developing hu1124, an anti-CD11a monoclonal antibody for psoriasis and organ transplant rejection, now in Phase I studies in psoriasis. XOMA's corporate strategy is to develop products from research through scaleup, clinical trials and regulatory approval, and to seek partners for commercialization, marketing and sale of approved products. Developing an expanded pipeline of products based on antibodies, the BPI protein, and peptides.
Product / Technology type(s) covered:
United States of America